Cargando…

Cardiovascular Risk Factors and Secondary Events Among Acute and Chronic Stable Myocardial Infarction Patients: Findings from a Managed Care Database

INTRODUCTION: Long-term risk for recurrent cardiovascular events among myocardial infarction (MI) patients in the acute versus chronic stable phase is not well characterized. This study was conducted to evaluate risk factors associated with all-cause mortality and cardiovascular (CVD) morbidity and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bash, Lori D., White, Kellee, Patel, Mehul D., Liu, Jinan, Mavros, Panagiotis, Mahaffey, Kenneth W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6828898/ https://www.ncbi.nlm.nih.gov/pubmed/31432429 http://dx.doi.org/10.1007/s40119-019-00147-5

Ejemplares similares

International Validation of the Thrombolysis in Myocardial Infarction (TIMI) Risk Score for Secondary Prevention in Post‐MI Patients: A Collaborative Analysis of the Chronic Kidney Disease Prognosis Consortium and the Risk Validation Scientific Committee
por: Mok, Yejin, et al.
Publicado: (2018)

Universal Classification System Type of Incident Myocardial Infarction in Patients With Stable Atherosclerosis: Observations From Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events (TRA 2°P)‐TIMI 50
por: Kidd, Stephen K., et al.
Publicado: (2016)

Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study)
por: Mahaffey, Kenneth W., et al.
Publicado: (2018)

Enzyme estimates of infarct size correlate with functional and clinical outcomes in the setting of ST-segment elevation myocardial infarction
por: Turer, Aslan T, et al.
Publicado: (2005)

Incidence and Predictors of Adverse Events Among Initially Stable ST‐Elevation Myocardial Infarction Patients Following Primary Percutaneous Coronary Intervention
por: Amon, Jaihoon, et al.
Publicado: (2022)

Cost-Effectiveness of Alirocumab for the Secondary Prevention of Cardiovascular Events after Myocardial Infarction in the Chinese Setting
por: Liang, Zhe, et al.
Publicado: (2021)

Acute myocardial infarction secondary to mucormycosis after lung transplantation
por: Naik, Chetan A., et al.
Publicado: (2020)

Consistent Reduction in Periprocedural Myocardial Infarction With Cangrelor as Assessed by Multiple Definitions: Findings From CHAMPION PHOENIX (Cangrelor Versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition)
por: Cavender, Matthew A., et al.
Publicado: (2016)

Repetitive Myocardial Infarctions Secondary to Delirium Tremens
por: Schwartzberg, David, et al.
Publicado: (2014)

Acute Myocardial Infarction Secondary to Paradoxical Embolism
por: Alenezi, Abdullah R, et al.
Publicado: (2020)

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial
por: Cavender, Matthew A., et al.
Publicado: (2015)

Immune and inflammatory responses in subjects with stable angina and acute myocardial infarction
por: Fang, Lu, et al.
Publicado: (2015)

Adding Insult to Injury: Are There Treatments for Myocardial Injury and Type 2 Myocardial Infarction?
por: White, Harvey D.
Publicado: (2020)

Long-term mortality, cardiovascular events, and bleeding in stable patients 1 year after myocardial infarction: a Danish nationwide study
por: Christensen, Daniel Mølager, et al.
Publicado: (2022)

Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
por: White, Harvey D, et al.
Publicado: (2019)

Methods of creatine kinase-MB analysis to predict mortality in patients with myocardial infarction treated with reperfusion therapy
por: Lopes, Renato D, et al.
Publicado: (2013)

Identification of a plasma metabolomic signature of thrombotic myocardial infarction that is distinct from non-thrombotic myocardial infarction and stable coronary artery disease
por: DeFilippis, Andrew P., et al.
Publicado: (2017)

Lifestyle variables and the risk of myocardial infarction in the General Practice Research Database
por: Delaney, Joseph AC, et al.
Publicado: (2007)

Validity of Myocardial Infarction Diagnoses in Administrative Databases: A Systematic Review
por: McCormick, Natalie, et al.
Publicado: (2014)

Infarct zone viability in stable patients with ST-elevation myocardial infarction not undergoing reperfusion - the COAT trial registry
por: Malek, Lukasz A, et al.
Publicado: (2011)

Secondary Prevention of Myocardial Infarction in People Living With HIV Infection
por: Erqou, Sebhat, et al.
Publicado: (2020)

ST-SEGMENT ELEVATION MYOCARDIAL INFARCTION SECONDARY TO COVID-19
por: DOUEDI, STEVEN, et al.
Publicado: (2021)

Risk of Parkinson Disease and Secondary Parkinsonism in Myocardial Infarction Survivors
por: Sundbøll, Jens, et al.
Publicado: (2022)

Disagreements between central clinical events committee and site investigator assessments of myocardial infarction endpoints in an international clinical trial: review of the PURSUIT study
por: Mahaffey, Kenneth W, et al.
Publicado: (2001)

Statewide declines in myocardial infarction and stroke emergency department visits during COVID-19 restrictions in North Carolina
por: Wong, Eugenia, et al.
Publicado: (2022)

Intra-operative events do not predict perioperative myocardial infarction
por: Appavu, SK, et al.
Publicado: (1998)

Electrocardiographic characteristics of posterior myocardial infarction in comparison to angiographic findings
por: Shemirani, Hasan, et al.
Publicado: (2015)

Cumulative Adherence to Secondary Prevention Guidelines and Mortality After Acute Myocardial Infarction
por: Solomon, Matthew D., et al.
Publicado: (2020)

Plasma Glycine and Risk of Acute Myocardial Infarction in Patients With Suspected Stable Angina Pectoris
por: Ding, Yunpeng, et al.
Publicado: (2015)

Immune Cell Repertoire and Their Mediators in Patients with Acute Myocardial Infarction or Stable Angina Pectoris
por: Yan, Wenwen, et al.
Publicado: (2017)

Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis
por: Bolland, Mark J, et al.
Publicado: (2010)

Acute Myocardial Infarction Manifested with Headache
por: Chatzizisis, Yiannis S, et al.
Publicado: (2010)

Randomised controlled trial of a secondary prevention program for myocardial infarction patients ('ProActive Heart'): study protocol. Secondary prevention program for myocardial infarction patients
por: Hawkes, Anna L, et al.
Publicado: (2009)

Recurrent ST-Elevation Myocardial Infarction (STEMI) in Coronary Artery Aneurysm Secondary to Atherosclerosis
por: Bhuiyan, Md, et al.
Publicado: (2022)

Secondary Prevention of Myocardial Infarction With Nonpharmacologic Strategies in a Medicaid Cohort
por: Oberg, Erica B., et al.
Publicado: (2009)

Vorapaxar: A novel agent to be considered in the secondary prevention of myocardial infarction
por: Kehinde, Obamiro, et al.
Publicado: (2016)

Non-ST elevation myocardial infarction secondary to carbon monoxide intoxication
por: Jankowska, Danuta, et al.
Publicado: (2017)

Going beyond the mean: economic benefits of myocardial infarction secondary prevention
por: von Wyl, Viktor, et al.
Publicado: (2020)

Mechanical Complication of Acute Myocardial Infarction Secondary to COVID-19 Disease
por: Damluji, Abdulla A., et al.
Publicado: (2022)

Mechanical Complication of Acute Myocardial Infarction Secondary to COVID-19 Disease
por: Damluji, Abdulla A., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_6ull2a80vpuibvuguhh2eug3bk